Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
3.080
-0.090 (-2.84%)
Feb 21, 2025, 4:00 PM EST - Market closed
Anixa Biosciences Employees
As of October 31, 2024, Anixa Biosciences had 5 total employees, including 4 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,510,800
Market Cap
99.16M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
ANIX News
- 5 days ago - Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial - PRNewsWire
- 9 days ago - Anixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview - PRNewsWire
- 12 days ago - Anixa Biosciences to Present at the 18th Annual European Life Sciences CEO Forum - PRNewsWire
- 19 days ago - Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention - PRNewsWire
- 4 weeks ago - Anixa Biosciences CEO Provides Letter to Shareholders - PRNewsWire
- 2 months ago - Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10 - PRNewsWire
- 3 months ago - Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset - PRNewsWire
- 3 months ago - Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial - PRNewsWire